Nuwellis To Implement 1-for-9 Reverse Stock Split; Stock Down
Nuwellis (NUWE) announced a 1-for-9 reverse stock split, effective October 27, 2026. The company reported Q2 2026 revenue of $2.0M, up 14% YoY, and a net loss of $4.8M. Shares are down 12.48% to $4.70.
How this was made
The 30-second read
Why it matters
The split and Q2 loss suggest short‑term downside, but the 14% revenue growth hints at a modest top‑line improvement.
Market read
Micro‑cap investors will reassess valuation post‑split; broader market impact is negligible.
What to watch
Potential upcoming FDA filings or new contract announcements could offset the negative bias from the split.
Background
NUWE is a medical‑device firm focused on ultrafiltration therapy devices. The reverse split reduces share count nine‑to‑one, changing the CUSIP and potentially affecting share liquidity.
Ticker impact
NUWE announced a 1-for-9 reverse stock split effective Oct 27, 2026 and reported Q2 2026 results.
likely downward pressure as the market prices in the split and recent loss
Reverse splits on micro‑caps typically trigger sell‑offs; the company also posted a net loss of $4.8 M, reinforcing negative sentiment.
Market effects
Limited impact beyond the niche ultrafiltration device market; may signal financing pressure for similar micro‑caps.
Primarily U.S. over‑the‑counter micro‑cap segment; no broader regional effect.
Minimal; the news is company‑specific.
Counterpoint
If the split consolidates the shareholder base, it could improve liquidity and set the stage for a future upside.
Key entities
- companyNuwellis, Inc.
Medical‑device company issuing the reverse split.
